Atossa Therapeutics Inc (ATOS)

[Hercules1]

UPDATE: Atossa Says Safety, Tolerability, Pharmacokinetic Objectives Were Successfully Met For Oral Endoxifen Phase 1 Study




 Safety: There were no clinically significant safety signals and no clinically significant adverse events in participants receiving oral Endoxifen.
 


– Tolerability: Oral Endoxifen was well tolerated at each dose level and for the dosing duration utilized in the study. 
– Pharmacokinetics: Oral Endoxifen demonstrated blood levels that have been associated with a therapeutic effect in the adjuvant setting in women with breast cancer.




These data demonstrate the suitability of oral Endoxifen for further clinical development.